^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Preliminary results of TQB2450 (PD-L1 blockade) plus anlotinib combined with oxaliplatin and capecitabine in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, multicenter phase II clinical trial.

Published date:
01/17/2023
Excerpt:
Pts with HER2-negative unresectable locally advanced or metastatic G/GEJ adenocarcinoma...In consequence, the preliminary ORR was 75.0% (95%CI: 50.9%~91.3%), DCR was 95.0% (95%CI: 75.1%~99.9%)….Preliminary results suggested that TQB2450 plus anlotinib combined with CAPEOX in first-line setting for advanced G/GEJ adenocarcinoma exhibited encouraging efficacy and manageable adverse events.
Secondary therapy:
CAPOX
DOI:
10.1200/JCO.2023.41.3_suppl.367
Trial ID: